Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents

Juan F. Iglesias,Dik Heg,Marco Roffi,David Tüller,Jonas Lanz,Fabio Rigamonti,Olivier Muller,Igal Moarof,Stéphane Cook,Daniel Weilenmann,Christoph Kaiser,Florim Cuculi,Marco Valgimigli,Peter Jüni,Stephan Windecker,Thomas Pilgrim

Five‐Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus‐Eluting Stents Versus Durable Polymer Everolimus‐Eluting Stents

2019

Juan F. Iglesias
Dik Heg
Marco Roffi
David Tüller
Jonas Lanz
Fabio Rigamonti
Olivier Muller
Igal Moarof
Stéphane Cook
Daniel Weilenmann
Christoph Kaiser
Florim Cuculi
Marco Valgimigli
Peter Jüni
Stephan Windecker
Thomas Pilgrim

Background The choice of optimal drug‐eluting stent therapy for patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention remains uncertain. We aimed to assess the long‐ter...

Keywords:

Cardiology
Diabetes mellitus
Sirolimus
Drug-eluting stent
Medicine
Internal medicine
Everolimus
Percutaneous coronary intervention
Surgery
Stent
Biodegradable polymer
in patient
everolimus eluting stent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations